# Hybrid histidine kinases and antifungal warfare in thermal dimorphic fungi

## TL;DR

This paper explores ambruticin, a new antifungal drug that targets specific proteins in fungi, offering a promising treatment for fungal infections with fewer side effects.

## Contribution

The paper introduces ambruticin as a novel antifungal targeting hybrid histidine kinases in thermal dimorphic fungi.

## Key findings

- Ambruticin targets hybrid histidine kinases, which are essential for fungal survival and morphological changes.
- The drug shows potential to treat multiple thermal dimorphic fungi without causing mechanism-based toxicity.

## Abstract

Thermal dimorphic fungal pathogens are fungi that infect humans, often through the inhalation of asexual conidia, and which transition from hyphae to yeast in the human body. These fungi cause severe or chronic mycoses and are typically treated with azoles or amphotericin B. Ambruticin, a polyketide antifungal, shows promise as an alternative therapy. It targets hybrid histidine kinases (HHKs), which are fungal-specific proteins essential for osmoregulation and parasitic morphology and are conserved across thermal dimorphic species. Targeting HHKs suggests that ambruticin may therapeutically treat infections from multiple fungi without causing mechanism-based toxicity. We explore ambruticin’s potential to effectively treat these fungal infections without major adverse effects.